Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy

Cancer development is driven by activated oncogenes and loss of tumor suppressors. While oncogene inhibitors have entered routine clinical practice, tumor suppressor reactivation therapy remains to be established. For the most frequently inactivated tumor suppressor p53, genetic mouse models have de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Klimovich, Boris, Mutlu, Samet, Schneikert, Jean, Elmshäuser, Sabrina, Klimovich, Maria, Nist, Andrea, Mernberger, Marco, Timofeev, Oleg, Stiewe, Thorsten
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2019
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825290/
https://ncbi.nlm.nih.gov/pubmed/31611375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1910255116
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados